Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma

Abstract

Aim: Lung adenocarcinoma (LUAD), the most prevalent subtype of non-small cell lung cancer (NSCLC), presents significant clinical challenges due to its high mortality and limited therapeutic options. The molecular heterogeneity and the development of therapeutic resistance further complicate treatment, underscoring the need for a more comprehensive understanding of its cellular and molecular characteristics. This study sought to delineate novel cellular subpopulations and molecular subtypes of LUAD, identify critical biomarkers, and explore potential therapeutic targets to enhance treatment efficacy and patient prognosis.

Methods: An integrative multi-omics approach was employed to incorporate single-cell RNA sequencing (scRNA-seq), bulk transcriptomic analysis, and genome-wide association study (GWAS) data from multiple LUAD patient cohorts. Advanced computational approaches, including Bayesian deconvolution and machine learning algorithms, were used to comprehensively characterize the tumor microenvironment, classify LUAD subtypes, and develop a robust prognostic model.

Results: Our analysis identified eleven distinct cellular subpopulations within LUAD, with epithelial cells predominating and exhibiting high mutation frequencies in Tumor Protein 53 (TP53) and Titin (TTN) genes. Two molecular subtypes of LUAD [consensus subtype (CS)1 and CS2] were identified, each showing distinct immune landscapes and clinical outcomes. The CS2 subtype, characterized by increased immune cell infiltration, demonstrated a more favorable prognosis and higher sensitivity to immunotherapy. Furthermore, a multi-omics-driven machine learning signature (MOMLS) identified ribonucleotide reductase M1 (RRM1) as a critical biomarker associated with chemotherapy response. Based on this model, several potential therapeutic agents targeting different subtypes were proposed.

Conclusion: This study presents a comprehensive multi-omics framework for understanding the molecular complexity of LUAD, providing insights into cellular heterogeneity, molecular subtypes, and potential therapeutic targets. Differential sensitivity to immunotherapy among various cellular subpopulations was identified, paving the way for future immunotherapy-focused research.

Keywords

Lung adenocarcinoma / tumor immune microenvironment / immunotherapy / molecular subtype / multiomics

References

[1] Siegel RL,Wagle NS.Cancer statistics, 2023.CA Cancer J Clin2023;73:17-48

[2] Allemani C,Di Carlo V.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.Lancet2018;391:1023-75 PMCID:PMC5879496

[3] Liu H,Li Z,Ren K.Bevacizumab loaded CalliSpheres® bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma.Front Pharmacol2023;14:1170344 PMCID:PMC10239861

[4] Boumelha J,Law EK.An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations.Cancer Res2022;82:3435-48 PMCID:PMC7613674

[5] Xiao Y,Wei J,Guo J.Recent progress in targeted therapy for non-small cell lung cancer.Front Pharmacol2023;14:1125547 PMCID:PMC9994183

[6] Laudadio E,Minnelli C.Chemical scaffolds for the clinical development of mutant-selective and reversible fourth-generation EGFR-TKIs in NSCLC.ACS Chem Biol2024;19:839-54

[7] Li Z,Pan CH.Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma.Cancer Discov2024;14:308-25 PMCID:PMC10922405

[8] Liang J,Huang Y.MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma.Drug Resist Updat2024;73:101057

[9] Puyalto A,López I.Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.Mol Cancer2024;23:78

[10] Hijazo-Pechero S,Cordero D.Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications.Mol Oncol2024;18:453-70 PMCID:PMC10850798

[11] Naqash AR,Mi E.Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.J Immunother Cancer2023;11:e007310 PMCID:PMC10603340

[12] Wang C,Song T.The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing.Signal Transduct Target Ther2022;7:289 PMCID:PMC9411197

[13] Moncada R,Wagner F.Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas.Nat Biotechnol2020;38:333-42

[14] Tan Z,Zuo J,Wang H.Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.J Transl Med2023;21:223 PMCID:PMC10044739

[15] Butler A,Smibert P,Satija R.Integrating single-cell transcriptomic data across different conditions, technologies, and species.Nat Biotechnol2018;36:411-20 PMCID:PMC6700744

[16] Pozniak J,Landeloos E.A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma.Cell2024;187:166-83.e25

[17] Ravi VM,Kueckelhaus J.Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma.Cancer Cell2022;40:639-55.e13

[18] Song X,Wu F.Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody.J Immunother Cancer2023;11:e006234 PMCID:PMC9980352

[19] Ma Y,Zhou Y.Polygenic regression uncovers trait-relevant cellular contexts through pathway activation transformation of single-cell RNA sequencing data.Cell Genom2023;3:100383 PMCID:PMC10504677

[20] Cao R,Wang G,Tian Y.An epithelial-mesenchymal transition (EMT) preoperative nomogram for prediction of lymph node metastasis in bladder cancer (BLCA).Dis Markers2020;2020:8833972 PMCID:PMC7656235

[21] Cao R,Ma B,Qiu W.An EMT-related gene signature for the prognosis of human bladder cancer.J Cell Mol Med2020;24:605-17 PMCID:PMC6933372

[22] Chen S,Shao J,Wang X.A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer.J Cancer2019;10:5744-53 PMCID:PMC6843883

[23] Jiang Y,Li C,Liang B.Development of an immune-related risk signature in patients with bladder urothelial carcinoma.Biomed Res Int2020;2020:5848493 PMCID:PMC7455840

[24] Jiang M,Chen Y.Identification of a hypoxia-related signature for predicting prognosis and the immune microenvironment in bladder cancer.Front Mol Biosci2021;8:613359 PMCID:PMC8138130

[25] Luo C,Hu J.A poliovirus receptor (CD155)-related risk signature predicts the prognosis of bladder cancer.Front Oncol2021;11:660273 PMCID:PMC8210672

[26] Na L,Sun Y.Identification of 9-core immune-related genes in bladder urothelial carcinoma prognosis.Front Oncol2020;10:1142 PMCID:PMC7360854

[27] Qiu H,He C,Li Y.Identification and validation of an individualized prognostic signature of bladder cancer based on seven immune related genes.Front Genet2020;11:12 PMCID:PMC7013035

[28] Quan J,Yu C.Bioinformatic identification of prognostic indicators in bladder cancer.Biomark Med2020;14:1243-54

[29] Shen C,Yang X.Construction of a immune-associated genes based prognostic signature in bladder cancer.Artif Cells Nanomed Biotechnol2021;49:108-19

[30] Shen C,Wang L,Niu H.Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer.Cancer Cell Int2020;20:538 PMCID:PMC7643334

[31] Shen C,Sun Y.Construction of an immune-associated gene-based signature in muscle-invasive bladder cancer.Dis Markers2020;2020:8866730 PMCID:PMC7785346

[32] Wang Z,Chen M.Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.BMC Cancer2021;21:692 PMCID:PMC8194149

[33] Wang Y,Yu M.Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.Cancer Med2020;9:7729-41 PMCID:PMC7571842

[34] Wu X,Cai C.A TP53-associated immune prognostic signature for the prediction of overall survival and therapeutic responses in muscle-invasive bladder cancer.Front Immunol2020;11:590618 PMCID:PMC7774015

[35] Wu Z,Li Z,Ye G.Identification and prognostic value of a glycolysis-related gene signature in patients with bladder cancer.Medicine2021;100:e23836 PMCID:PMC7837905

[36] Xing Q,Jiang S,Wang Z.Prognostic model of 10 immune-related genes and identification of small molecule drugs in bladder urothelial carcinoma (BLCA).Transl Androl Urol2020;9:2054-70 PMCID:PMC7658175

[37] Yan Y,Cai J.Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.Aging2020;13:2780-802 PMCID:PMC7880321

[38] Yan X,Guo ZX,Li S.Identification of Hub genes associated with progression and prognosis in patients with bladder cancer.Front Genet2019;10:408 PMCID:PMC6513982

[39] Yan X,Chen Z.Construction and validation of an autophagy-related prognostic signature and a nomogram for bladder cancer.Front Oncol2021;11:632387 PMCID:PMC8252967

[40] Yan X,Guo ZX,Liu TZ.Construction and validation of an eight-gene signature with great prognostic value in bladder cancer.J Cancer2020;11:1768-79 PMCID:PMC7052873

[41] Yin H,Gou X,Gan D.Identification of a 13-mRNA signature for predicting disease progression and prognosis in patients with bladder cancer.Oncol Rep2020;43:379-94 PMCID:PMC6967157

[42] Yang F,Shen Y.Cribriform growth pattern in lung adenocarcinoma: more aggressive and poorer prognosis than acinar growth pattern.Lung Cancer2020;147:187-92

[43] Zhou C,Wang Y.Predicting lung adenocarcinoma prognosis with a novel risk scoring based on platelet-related gene expression.Aging2021;13:8706-19 PMCID:PMC8034940

[44] Erin N,Brozovic A.Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.Drug Resist Updat2020;53:100715

[45] Li F,Huang Y.Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer.Drug Resist Updat2024;73:101059

[46] Lu W.Epithelial-mesenchymal plasticity in cancer progression and metastasis.Dev Cell2019;49:361-74 PMCID:PMC6506183

[47] Flórez MM,da Silva GN.Cell cycle kinetics, apoptosis rates and gene expressions of MDR-1, TP53, BCL-2 and BAX in transmissible venereal tumour cells and their association with therapy response.Vet Comp Oncol2017;15:793-807

[48] Sun P,Lu Q.Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast.Mod Pathol2020;33:1945-60

[49] Imamura T,Ohshima K.Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma.BMC Cancer2022;22:1046 PMCID:PMC9535898

[50] Kaiser AM,Hanson KJ.p53 governs an AT1 differentiation programme in lung cancer suppression.Nature2023;619:851-9 PMCID:PMC11288504

[51] Djulbegovic MB,Karp CL.Functional impact of titin (TTN) mutations in ocular surface squamous neoplasia.Int J Biol Macromol2022;195:93-101

[52] Lakshmanan I,Seshacharyulu P.MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53.Clin Cancer Res2017;23:3906-17 PMCID:PMC5511558

[53] Bao X,Chen J.Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-assisted multiomics analysis.Cancer Immunol Res2022;10:811-28

[54] Golino JL,Maeng HM.Revealing the heterogeneity of the tumor ecosystem of cholangiocarcinoma through single-cell transcriptomics.Cells2023;12:862 PMCID:PMC10047686

[55] Zhang J,Dai W.Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion.Cancer Immunol Immunother2024;73:71 PMCID:PMC10908647

[56] McLaughlin M,Pedersen M.Inflammatory microenvironment remodelling by tumour cells after radiotherapy.Nat Rev Cancer2020;20:203-17

[57] Park S,Kim H.Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer.J Clin Oncol2022;40:1916-28 PMCID:PMC9177249

[58] Li Y,Chai Z.Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.Gut2023;72:2307-20 PMCID:PMC10715532

[59] Váraljai R,Al-Matary Y.Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.Nat Cancer2023;4:1292-308 PMCID:PMC10518254

[60] Bepler G,Cantor A.RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer.J Clin Oncol2004;22:1878-85

[61] Gautam A,Bepler G.RRM1-induced metastasis suppression through PTEN-regulated pathways.Oncogene2003;22:2135-42

[62] Gautam A.Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase.Cancer Res2006;66:6497-502

[63] Vilmar AC,Sorensen JB.Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.Ann Oncol2013;24:309-14

[64] Gong W,Wu J.RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.Lung Cancer2012;75:374-80

[65] Bepler G,Sharma S.RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.J Clin Oncol2006;24:4731-7

[66] Chu G,Wang Y.Integrated multiomics analysis and machine learning refine molecular subtypes and prognosis for muscle-invasive urothelial cancer.Mol Ther Nucleic Acids2023;33:110-26 PMCID:PMC10336357

[67] Ji M,Choi SJ.Plasma metabolomics and machine learning-driven novel diagnostic signature for non-alcoholic steatohepatitis.Biomedicines2022;10:1669 PMCID:PMC9312563

[68] Zhang J,Ying H.Refining molecular subtypes and risk stratification of ovarian cancer through multi-omics consensus portfolio and machine learning.Environ Toxicol2024;Online ahead of print:

[69] Rönn T,Oskolkov N.Predicting type 2 diabetes via machine learning integration of multiple omics from human pancreatic islets.Sci Rep2024;14:14637 PMCID:PMC11199577